Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Trabectedin

FDA-approved product (powder, intravenous), marketed as Evdi, Yondelis.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Trabectedin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Dedifferentiated liposarcoma
  • Leiomyosarcoma
  • Liposarcoma
  • Neoplasm
  • Ovarian cancer
  • Ovarian carcinoma
  • Ovarian neoplasm
  • Sarcoma
  • Soft tissue sarcoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other plant alkaloids and natural products
FDA pharmacologic class
Alkylating Drug FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae47.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis76.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Trabectedin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Trabectedin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS

    NCT07076186 · start 2025-10-02

    Registered record
    Registry ID
    NCT07076186
    Conditions
    Uterine Leiomyosarcoma
    Interventions
    Trabectedin; Doxorubicin Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-10-02
    Completion
    2029-12-02
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUterine Leiomyosarcoma
    InterventionTrabectedin; Doxorubicin Hydrochloride
    PhasePhase 2
    Registry statusRecruiting

  • Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

    NCT06524583 · start 2025-01-27

    Registered record
    Registry ID
    NCT06524583
    Conditions
    Leiomyosarcoma Uterus
    Interventions
    Doxorubicin; Trabectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-01-27
    Completion
    2030-12
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeiomyosarcoma Uterus
    InterventionDoxorubicin; Trabectedin
    PhasePhase 2
    Registry statusRecruiting

  • Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

    NCT05432791 · start 2023-03-30

    Registered record
    Registry ID
    NCT05432791
    Conditions
    Locally Advanced Uterine Corpus Leiomyosarcoma; Metastatic Uterine Corpus Leiomyosarcoma; Stage III Uterine Corpus Leiomyosarcoma AJCC v8; Stage IV Uterine Corpus Leiomyosarcoma AJCC v8; Unresectable Uterine Corpus Leiomyosarcoma
    Interventions
    Biospecimen Collection; Bone Scan; Computed Tomography; Magnetic Resonance Imaging; Multigated Acquisition Scan; Olaparib; Pazopanib; Temozolomide; Trabectedin; Transthoracic Echocardiography Test
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2023-03-30
    Completion
    2027-01-30
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Uterine Corpus Leiomyosarcoma; Metastatic Uterine Corpus Leiomyosarcoma; Stage III Uterine Corpus Leiomyosarcoma AJCC v8; Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 +1 more
    InterventionBiospecimen Collection; Bone Scan; Computed Tomography; Magnetic Resonance Imaging +6 more
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • tTF-NGR Randomized Study - STS

    NCT05597917 · start 2021-10-26

    Registered record
    Registry ID
    NCT05597917
    Conditions
    Soft Tissue Sarcoma
    Interventions
    Trabectedin; tTF-NGR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2021-10-26
    Completion
    2026-12
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSoft Tissue Sarcoma
    InterventionTrabectedin; tTF-NGR
    PhasePhase 3
    Registry statusRecruiting

  • Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

    NCT04305548 · start 2021-09-14

    Registered record
    Registry ID
    NCT04305548
    Conditions
    Mesenchymal Chondrosarcoma
    Interventions
    Trabectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-09-14
    Completion
    2026-12-31
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMesenchymal Chondrosarcoma
    InterventionTrabectedin
    PhasePhase 2
    Registry statusRecruiting

  • Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma

    NCT04535271 · start 2021-09-09

    Registered record
    Registry ID
    NCT04535271
    Conditions
    Leiomyosarcoma
    Interventions
    Trabectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-09-09
    Completion
    2029-03-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeiomyosarcoma
    InterventionTrabectedin
    PhasePhase 2
    Registry statusRecruiting

  • Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas

    NCT05131386 · start 2021-05-28

    Registered record
    Registry ID
    NCT05131386
    Conditions
    Soft Tissue Sarcoma; Bone Tumors; Small Round-cell Sarcomas
    Interventions
    Trabectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-05-28
    Completion
    2024-07-28
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSoft Tissue Sarcoma; Bone Tumors; Small Round-cell Sarcomas
    InterventionTrabectedin
    PhasePhase 2
    Registry statusUnknown

  • Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.

    NCT03838744 · start 2020-05-20

    Registered record
    Registry ID
    NCT03838744
    Conditions
    Advanced Soft Tissue Sarcoma
    Interventions
    Standard arm: Trabectedin in monotherapy; Experimental arm: Trabectedin + Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-05-20
    Completion
    2024-11-29
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Soft Tissue Sarcoma
    InterventionStandard arm: Trabectedin in monotherapy; Experimental arm: Trabectedin + Olaparib
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

    NCT03690739 · start 2019-08-09

    Registered record
    Registry ID
    NCT03690739
    Conditions
    Recurrent Ovarian Carcinoma
    Interventions
    Carboplatin; Gemcitabine; Bevacizumab; PLD; Paclitaxel; PLD; Trabectedin; Cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2019-08-09
    Completion
    2021-03-03
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Ovarian Carcinoma
    InterventionCarboplatin; Gemcitabine; Bevacizumab; PLD +4 more
    PhasePhase 3
    Registry statusTerminated

  • Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

    NCT03886311 · start 2019-05-15

    Registered record
    Registry ID
    NCT03886311
    Conditions
    Sarcoma
    Interventions
    Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]; Nivolumab IV Soln 100 MG/10ML; Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2019-05-15
    Completion
    2031-07-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    InterventionTalimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]; Nivolumab IV Soln 100 MG/10ML; Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
    PhasePhase 2
    Registry statusRecruiting

  • Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors

    NCT03496519 · start 2018-10-01

    Registered record
    Registry ID
    NCT03496519
    Conditions
    Solid Tumor, Adult
    Interventions
    Dose Escalation of Durvalumab and Trabectedin; Dose Expansion of Durvalumab and Trabectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2018-10-01
    Completion
    2021-10-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor, Adult
    InterventionDose Escalation of Durvalumab and Trabectedin; Dose Expansion of Durvalumab and Trabectedin
    PhasePhase 1
    Registry statusWithdrawn

  • Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma

    NCT03470805 · start 2018-06-21

    Registered record
    Registry ID
    NCT03470805
    Conditions
    Ovarian Cancer
    Interventions
    Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-06-21
    Completion
    2022-07-27
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    InterventionOlaparib
    PhasePhase 2
    Registry statusCompleted

  • Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma

    NCT03397186 · start 2018-06-19

    Registered record
    Registry ID
    NCT03397186
    Conditions
    Myxoid Liposarcoma; Round Cell Liposarcoma; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Metastatic Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma
    Interventions
    Biopsy; Laboratory Biomarker Analysis; Trabectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2018-06-19
    Completion
    2021-05-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyxoid Liposarcoma; Round Cell Liposarcoma; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7 +2 more
    InterventionBiopsy; Laboratory Biomarker Analysis; Trabectedin
    PhasePhase 2
    Registry statusWithdrawn

  • Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor

    NCT03023124 · start 2018-03-04

    Registered record
    Registry ID
    NCT03023124
    Conditions
    Solitary Fibrous Tumors
    Interventions
    Trabectedin; Adriamycin; Dacarbazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-03-04
    Completion
    2024-12-06
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolitary Fibrous Tumors
    InterventionTrabectedin; Adriamycin; Dacarbazine
    PhasePhase 2
    Registry statusCompleted

  • QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer

    NCT03164980 · start 2018-02-01

    Registered record
    Registry ID
    NCT03164980
    Conditions
    Quality of Life; Ovarian Cancer; Recurrent Ovarian Carcinoma
    Interventions
    Trabectidin (Yondelis)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2018-02-01
    Completion
    2023-08-08
    Enrolment
    89

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionQuality of Life; Ovarian Cancer; Recurrent Ovarian Carcinoma
    InterventionTrabectidin (Yondelis)
    PhasePhase 4
    Registry statusTerminated